Development of an injectable PHBV microparticles-GG hydrogel hybrid system for regenerative medicine by Pacheco, Daniela P. et al.
International Journal of Pharmaceutics 478 (2015) 398–408Pharmaceutical nanotechnology
Development of an injectable PHBV microparticles-GG hydrogel hybrid
system for regenerative medicine
Daniela P. Pacheco a,b,c,*, Maria H. Amaral c, Rui L. Reis a,b, Alexandra P. Marques a,b,
Vítor M. Correlo a,b,*
a 3B’s Research Group – Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue
Engineering and Regenerative Medicine, AvePark, 4806-909 Taipas, Guimarães, Portugal
b ICVS/3B’s – PT Government Associate Laboratory, Braga/Guimarães, Portugal
c Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
A R T I C L E I N F O
Article history:
Received 22 August 2014
Received in revised form 13 November 2014
Accepted 14 November 2014
Available online 18 November 2014
Keywords:
Polyhydroxybutyrate-co-hydroxyvalerate
Gellan gum
Microparticulate systems
Injectable hydrogel
Regenerative medicine
A B S T R A C T
Uncontrollable displacements that greatly affect the concentration of active agents at the target tissues
are among a major limitation of the use of microparticulate drug delivery systems (DDS). Under this
context a biphasic injectable DDS combining poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV)
microparticles (MPs) and a gellan gum (GG) injectable hydrogel is herein proposed for the localized
delivery and long-term retention of MPs carrying hydrophilic and hydrophobic model active agents. A
double emulsion-solvent evaporation method was adopted to develop the PHBV MPs, carrying bovine
serum albumin (BSA) or dexamethasone (Dex) as hydrophilic and hydrophobic active agents’ models,
respectively. Moreover, this method was modiﬁed, together with the properties of the hydrogel to tailor
the delivery proﬁle of the active agents. Variations of the composition of the organic phase during the
process allowed tuning surface topography, particle size distribution and core porosity of the PHBV MPs
and, thus, the in vitro release proﬁle of Dex but not of BSA. Besides, after embedding hydrogels of higher
GG concentration led to a slower and more sustained release of both active agents, independently of the
processing conditions of the microparticulate system.
ã 2014 Elsevier B.V. All rights reserved.
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The design and production of efﬁcient drug delivery systems
(DDS) are of vital importance in tissue engineering (TE) and
regenerative medicine (RM) (Biondi et al., 2008). Ideally, DDS
intend to sustain a particular active agents’ concentration in
patients’ blood and/or tissues for a deﬁned and extended time,
avoiding repeated administration (Amass et al., 1998; Kost and
Langer, 2001). Injectable DDS that have been proposed so far rely
on liposomes (Monteiro et al., 2013), micelles (Xu et al., 2013),
polymeric micro- and nanoparticles (Kozielski et al., 2013; Liang
et al., 2013), cyclodextrins (Dhule et al., 2012), among others
(Oliveira et al., 2011).* Corresponding author at: 3B’s Research Group – Biomaterials, Biodegradables
and Biomimetics, Department of Polymer Engineering, University of Minho,
Headquarters of the European Institute of Excellence on Tissue Engineering and
Regenerative Medicine, AvePark, Taipas, 4806-909 Guimarães, Portugal; ICVS/3B’s,
Associate Laboratory, PT Government Associate Laboratory, Guimarães, Braga,
Portugal. Tel.: +351 918236302.
E-mail address: vitorcorrelo@dep.uminho.pt (V.M. Correlo).
http://dx.doi.org/10.1016/j.ijpharm.2014.11.036
0378-5173/ã 2014 Elsevier B.V. All rights reserved.A number of different polymers, either synthetic or natural,
have been exploited for the production of biodegradable DDS.
These systems are cleaved through chemical or enzyme-catalyzed
hydrolysis thus allowing the release of the active agent in a
controlled manner and at a sustained concentration, within its
therapeutic window. The release proﬁles of the active agents from
biodegradable polymers, in addition to a dependence with the
degradation mechanism and kinetics of the polymers (Ciçek et al.,
1995; Mi et al., 2002; Zhang and Chu, 2002), can be controlled by a
number of other factors, such as physicochemical properties of the
polymers and active agents (Calandrelli et al., 2002; Abraham et al.,
2003), thermodynamic compatibility between the polymers and
active agents (Liu et al., 2004), as well as the shape of the devices
(Chen and Lee, 2001; Tunón et al., 2003; Fulzele et al., 2004).
Among the biodegradable polymers that have been explored for
the production of DDS, poly(lactide-co-glycolide) (Wen et al., 2013),
poly(L-lactic acid) (Correia et al., 2013), chitosan (Champa and Bhat,
2010), alginate (Iwanaga et al., 2013), starch-poly-e-caprolactone
(Balmayor et al., 2009) and polyhydroxyalkanoates (PHAs) are the
most used. From the PHA family, polyhydroxybutyrate (PHB) and its
co-polymer with hydroxyvalerate (PHBV) in particular, in addition
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delivery systems for various active agents (Shishatskaya et al.,
2008; Chen and Tong, 2012; Kabilan et al., 2012). PHAs micro-
particles (MPs) have been developed by different microencapsula-
tion approaches that rely on solvent-evaporation methods,
emulsiﬁcation–diffusion, among others. The ﬁrst approach offers
advantages over other methods, since it is highly reproducible,
presents the ability to serve as carriers of hydrophilic and
hydrophobic active agents with high incorporation efﬁciency,
which release proﬁle can also be controlled by the processing
factors (Ogawa et al., 1988; Yeo et al., 2001). On the other hand, the
emulsiﬁcation–diffusion is a very versatile technique, in which
different types of emulsions can be used, though oil/water
emulsions are of interest because they use water as the nonsolvent,
simpler and more economic, since it facilitates the washing step
and minimizes agglomeration (Pinto Reis et al., 2006). However,
this method can only be applied to hydrophobic active agents, and
limitations are imposed by the scale-up of the high energy
requirements in homogenization (Soppimath et al., 2001). Relying
on these microencapsulation methods, different applications have
been proposed. In studies of antibiotic delivery, gentamicin was
incorporated into PHAs MPs to prevent infections associated with
bone implants and scaffolds (Francis et al., 2011), whilst Rodríguez-
Contreras produced PHAs MPs to delivery doxycycline (Rodríguez-
Contreras et al., 2013). Moreover, Poletto and co-workers adopted
the emulsiﬁcation–diffusion technique using a binary mixture of
different proportions of chloroform and ethanol aiming to decrease
the size of the particles (Poletto et al., 2008).
Although the microparticulate systems present many advan-
tages, upon injection they are continuously exposed to external
mechanical deformation, leading to uncontrollable displacements
(Fitzgerald et al., 1987; Grifﬁth, 2000; Chan and So, 2005). This
greatly affects the concentration of active agents at the target
tissues, which can lead to impaired outcomes, such as, for example,
limited tissue regeneration (Lemperle et al., 2004). Moreover,
when in free movement the particulate system can be expelled
before the release of the active agent. Therefore, extensive efforts
are being made to tackle this issue while harnessing the
advantages of particulate systems, including their minimally
invasive administration and the controlled delivery of the active
agent. In this sense, the incorporation of MPs in injectable
hydrogels was hypothesized in order to develop a minimally-
invasive DDS that would provide MPs localized delivery avoiding
uncontrolled migration through the human body, along with a
sustained release of an active agent.
From the clinical point of view, injectable hydrogels formed by in
situ polymerization are highly desirable due to: (1) enabling
minimally invasive application; (2) high capacity to adapt to the
tissue defect; and (3) high compatibility with incorporated active
agents and cells if desired (Jin, 2012). In this regard, gellan gum (GG)
hydrogels that have been shown to be a suitable platform to support
and deliver cells in different TE applications as extensively
characterized in our Group, were selected (Coutinho et al., 2010;
Oliveira et al., 2010; da Silva et al., 2014). The double emulsiﬁcation–
solvent evaporation method described by Ogawa et al. (1988) was
adopted to develop PHBV MPs, carrying bovine serum albumin
(BSA) or dexamethasone (Dex) as hydrophilic and hydrophobic
active agents’ models, respectively. This method is highly
reproducible and has been extensively used to create particles
with a spherical and inner core-shell structure that can serve as
carrier of water-soluble and insoluble active agents. The character-
istics of the produced MPs are largely dependent on the type of
polymer (hydrophobic/hydrophilic) and active agent used. Thus,
this method was modiﬁed, together with the properties of the
hydrogel to tailor the delivery proﬁle of the active agents. In this
way, a new in situ gelling injectable system, incorporating PHBVMPs loaded with both relevant hydrophilic and hydrophobic
molecules, which allows their localized and controlled release is
herein proposed.
2. Materials and methods
2.1. Preparation of PHBV MPs
The PHBV (molecular weight (Mw) = 425,692 g mol1) (PHB
Industrial S.A., Brazil) MPs were prepared by using a modiﬁcation
of the double emulsiﬁcation–solvent evaporation method previ-
ously described by Ogawa (Ogawa et al., 1988). Brieﬂy, 3 mL of a
0.5% (w/v) poly(vinyl alcohol) (PVA) (Sigma–Aldrich, Germany)
aqueous solution (W1) was mixed with 15 mL of a 3% (w/v) PHBV
solution in chloroform–ethanol (O). Two different ratios of
chloroform–ethanol were used in order to verify its effect over
the release proﬁle of the active agents, namely 100:0 chloroform:
ethanol (absence of ethanol) and 90:10 chloroform:ethanol
(presence of ethanol). The mixture was emulsiﬁed for 3 min using
an Ultra-Turrax T18 (IKA-Werke, Germany) in order to obtain the
ﬁrst emulsion (W1/O). The primary emulsion was then dropped
into 150 mL of 1% (w/v) PVA solution (W2) and homogenized (RW
16 basic IKA-Werke, Germany) during 5 min forming the secondary
emulsion (W1/O/W2). The ﬁnal W1/O/W2 emulsion was left to
evaporate under magnetic stirring and the obtained MPs were
collected by centrifugation, washed at least three times with
deionized water and freeze-dried. BSA was dissolved at a
concentration of 0.1% (w/v) within the ﬁrst aqueous phase (W1),
whilst Dex was dissolved in the organic phase at a ﬁnal
concentration of 3.3  103% (w/v). Unloaded-MPs were also
prepared, as control, using the same protocol previously described,
but in the absence of the active agents.
2.2. Incorporation of PHBV MPs in GG hydrogels
For the preparation of the injectable GG hydrogels, a previously
described procedure was followed (da Silva et al., 2014). Gelzan CM
(Sigma–Aldrich, Germany) powder was mixed at room tempera-
ture with deionized water at two different concentrations, 0.75%
(w/v) and 1.25% (w/v), under constant stirring. The solution was
heated at 90 C and kept at this temperature for 30 min.
Afterwards, 30 mg of active agent-loaded PHBV MPs were
dispersed with 20 mL of GG solution. Subsequently, calcium
chloride (VWR, USA) was added to this solution at a concentration
of 0.18% (w/v) to act as crosslinker. Finally, the solution was left at
room temperature during approximately one hour, allowing the
formation of the gel, which was then maintained in a phosphate-
buffered saline (PBS) solution.
2.3. Quantiﬁcation of the MPs’ production yield
The yield of the particles prepared under the different
conditions deﬁned in Section 2.1 was calculated using Eq. (1).
yield %ð Þ ¼ wx
wy
 100 (1)
The yield was calculated based on the weight of MPs (wx) and
the weight of the compounds used to prepare the MPs (wy),
polymer or polymer plus active agent.
2.4. Quantiﬁcation of the incorporation efﬁciency of Dex and BSA into
the PHBV MPs
Aiming at determining the BSA incorporation efﬁciency (IE) into
the MPs, 10 mg of BSA- or Dex-loaded MPs were completely
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temperature for 24 h. This allows the dissolution of PHBV and at
the same time permits the release of the entrapped active agent.
Then, 10 mL of PBS was added in order to dissolve the BSA/Dex.
After centrifugation, the supernatant was collected and ﬁltered
through a 0.2 mm membrane. The concentration of the incorpo-
rated BSA was measured using the Micro BCATM Protein Assay Kit
(Pierce, IL) following manufacturer’s instructions. Optical density
of the BSA- and Dex-containing solutions was measured at 562 and
242 nm, respectively, in a Synergy HT multi-detection microplate
reader (Bio-Tek’s Gen5TM, USA). The amounts of BSA and Dex
within the MPs were obtained from the calibration curves. The IE of
the active agents within PHBV MPs was calculated using Eq. (2) as
follows:
IE %ð Þ ¼ BSA or Dex½ within MPs
Initial BSA or Dex½   100 (2)
2.5. In vitro release studies
In vitro release of BSA and Dex from PHBV MPs was evaluated up
to 21 days. For that, 30 mg of MPs were incubated in 10 mL of PBS
(0.01 M, pH 7.4), and maintained in a precision water bath (Grant,
UK) at 60 rpm and 37.0  0.5 C. At deﬁned time points, 1 mL of
supernatant was collected and an equivalent amount of fresh PBS
at 37.0  0.5 C was added to maintain the total volume of the
sample. The amount of released BSA and Dex was determined as
described above. A similar procedure was followed to determine
the release proﬁle of BSA and Dex from the PHBV MPs embedded
within the GG hydrogels.Fig. 1. Unloaded-PHBV MPs physicochemical properties. (A) Yield of the process and
comparing the PHBV MPs produced in the absence and in the presence of ethanol. (B) SE
ethanol in the organic phase. The sequential micrographs represent (i and iv) an overview
internal morphology.2.6. Analysis of the kinetics and mechanism of release
The release mechanism of BSA and Dex from both PHBV MPs
and PHBV MPs embedded in GG hydrogels was analyzed by
applying the results in different kinetic models (Costa and Sousa
Lobo, 2001). The zero-order that explains the active agent release
rate as an independent phenomenon of the active agent
concentration (Donbrow and Samuelov, 1980). The ﬁrst-order
usually applied to active agent dissolution studies (Gibaldi and
Feldman, 1967; Wagner, 1969). The Higuchi that is concerned on
the release of water soluble and low soluble active agents
incorporated in semi-solid and/or solid matrices, and describes
the active agent release as a diffusion process based on Fickian
diffusion (Higuchi, 1961, 1963). And the Korsmeyer–Peppas,
generally used to analyze the release of pharmaceutical polymeric
dosage forms, when the release mechanism is not well known or
when more than one type of release phenomena could be involved
(Korsmeyer and Peppas, 1981; Korsmeyer et al., 1983; Costa and
Sousa Lobo, 2001), were the applied models. The determination
coefﬁcient (R2) was used as an indicator of the best ﬁtting of the
data for each model. R2 and model parameters of the release
proﬁles were calculated using SigmaPlot 12.5 software (Systat
Software Inc., USA).
2.7. Laser diffraction spectrometry
The size distribution of the prepared MPs was measured by
laser diffraction spectrometry (Coulter LS 230, Coulter Electronics,
USA). The dried samples were suspended in a 0.2% (w/v) Tween1
80 (Sigma–Aldrich, Germany) solution and sonicated for 5 min
with an ultra-sound probe (Sonoswiss SW 6H, Sonoswiss1 AG, size of the PHBV MPs produced under different conditions. *p < 0.05, **p < 0.01
M micrographs of PHBV MPs obtained in the (i–iii) absence and (iv–vi) presence of
 of the obtained MPs, (ii and v) the detail of their surface and (iii and vi) respective
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suspension was used for the particle size distribution analysis.
2.8. Fourier transform infrared spectroscopy
Fourier transform infrared spectroscopy (FTIR) analyses, under
Transmission mode, were performed in order to analyze PHBV MPs
(unloaded, loaded and after release) chemical composition. With
this purpose, 1 mg of MPs were mixed with 40 mg of potassium
bromide (KBr) and then processed into a disc in a manual press
(161–1100 hand press, Pike technologies, Madison, WI). FTIR-KBr
spectra (IR Prestige 21, Shimadzu, Japan) were recorded at 40 scans
with a resolution of 4 cm1, from 1400 to 4000 cm1.
2.9. Scanning electron microscopy
The morphology of the PHBV MPs and PHBV MPs embedded
within GG hydrogels was analyzed before and after the in vitro
release studies, by scanning electron microscopy (SEM) using a
S360 microscope (Leica Cambridge, UK). Before being analyzed, the
different structures were gold sputter coated (Fisons instruments,
UK) for 2 min at 15 mA. Micrographs were recorded at 5.0 kV and
different magniﬁcations.
2.10. Rheological analysis
Cone–plate rheometry was conducted for GG hydrogels with
and without embedded PHBV MPs to assess their rheological
behavior as function of temperature and time. For this purpose, in
each measurement, a volume of 2 mL of the sample was placed in
the bottom plate of the rheometer (Malvern Kinexus Rotational
Rheometer, UK) and allowed to stabilize for 1 min at a constant
temperature of 5 C before starting the analysis. Measurements
were performed by increasing the temperature from 5 to 50 C (atFig. 2. BSA and Dex loaded-PHBV MPs physicochemical properties. (A) Yield of the proces
***p < 0.001 comparing the loaded and unloaded-PHBV MPs produced under the same
loaded-PHBV MPs obtained in the (i and ii) absence; and (iii and iv) presence of ethanol i
the obtained MPs and (ii and iv) the detail of their surface.a heating rate of 1 C/min) and applying a constant shear stress of
0.1 Pa.
2.11. Statistical analysis
The results of at least three independent experiments are
presented as mean  standard deviation (SD). The yield, particle
size and IE data were analyzed using the one-way analysis of
variance (ANOVA) (a = 0.05) and Tukey’s multiple comparison test
using Graphpad Prism version 5 (Graphpad Software, USA).
Signiﬁcance differences were set for p < 0.05.
3. Results
3.1. Effect of processing method over PHBV MPs properties
The PHBV MPs were produced following a double emulsiﬁ-
cation–solvent evaporation method using a mixture of chloroform:
ethanol in two different proportions in order to assess the effect of
the processing conditions over the MPs properties and subsequent
incorporation capacity and release proﬁle of BSA and Dex. The yield
in the preparation of PHBV MPs (Fig. 1A) revealed to be
signiﬁcantly (p < 0.05) affected by the solvent composition. The
results showed that the presence of ethanol in the organic phase
led to a decreased of 6% in the yield. Likewise, the size distribution
of the MPs was also signiﬁcantly (p < 0.01) affected by the
processing conditions. The mean particle size of unloaded-MPs
obtained in the presence of ethanol (around 58 mm) was found to
be larger than in its absence (around 42 mm), with a distribution of
range from 15.6 to 76.4 mm and 5.6 to 91.1 mm, respectively.
Concerning the morphology of the produced MPs (Fig. 1B),
perfect spherical shape MPs were obtained independently of the
processing conditions (Fig. 1B; i and iv). However, a detailed
analysis of MPs surface topography revealed rough surfaces, boths and size of the PHBV MPs produced under different conditions. *p < 0.05, **p < 0.01,
 conditions and incorporating the same active agent. (B) SEM micrographs of BSA
n the organic phase. The sequential micrographs represent an (i and iii) overview of
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topography (Fig. 1B; ii and v). Moreover, both in the presence and
absence of ethanol, MPs presented a porous core (Fig.1B; iii and vi).
Nonetheless, the addition of ethanol to the organic phase led to the
formation of larger pore in the inner structure (Fig. 1B; vi).
3.2. Loaded-MPs properties
3.2.1. BSA and Dex entrapment
The impact of the incorporation of active agents within PHBV
MPs over the process yield and particle size was determined
(Fig. 2A). While no signiﬁcant differences were observed in terms
of yield when producing unloaded-PHBV MPs (Fig. 1A) and active
agent-loaded MPs (Fig. 2A) (p > 0.05), the size of the loaded-PHBV
MPs was affected by the incorporation of the active agents
(Fig. 2A). In the absence of ethanol, the mean size of the loaded-
PHBV MPs, independently of the incorporated agent, was
signiﬁcantly higher than the unloaded-MPs. This difference was
not observed in the presence of ethanol. Furthermore, the mean
MPs size signiﬁcantly increased with the molecular weight (Mw) of
the active agent that was incorporated. Thus, the BSA-loaded PHBV
MPs exhibited a higher mean particle size when compared with the
BSA-loaded PHBV MPs (Fig. 2A).
The SEM analysis of the loaded-PHBV MPs conﬁrmed not only the
particlesizemeasurements,butalsothemaintenanceofthespherical
morphology after incorporation of the active agents (Fig. 2B; i and
iii), which was independent of the incorporated molecule.
The IE of BSA and Dex within the PHBV MPs obtained under
different experimental conditions revealed to be independent of
the processing conditions (p > 0.05). An IE around 66% was
achieved for BSA both in presence and absence of ethanol
(Fig. 3A). Although not signiﬁcantly different (p > 0.05), the
presence of ethanol in the organic phase resulted in higher
(around 92% vs 82%) IE of Dex. Moreover, the Dex IE was
signiﬁcantly higher than BSA.
The entrapment of BSA and Dex within PHBV MPs was further
conﬁrmed by FTIR analysis (Fig. 3B and C). The IR peaks of pure BSA
at 1652 and 1531 cm1 are assigned to stretching vibration of
amide I (mainly C¼O stretching vibrations), and amide II (the
coupling of bending vibrate of N–H and stretching vibrate of C–N)Fig. 3. PHBV MPs characterization after incorporation of BSA and Dex (A) IE of BSA and De
PHBV MPs. (C) FTIR spectra of Dex before and after incorporation of Dex within PHBV Mbands, respectively. The FTIR spectra of BSA-loaded PHBV MPs
revealed these characteristic bands of both the polymer and the
protein, indicating that the hydrophilic active agent was success-
fully incorporated. Similarly, the FTIR analysis also conﬁrmed the
successful entrapment of Dex inside the PHBV MPs (Fig. 3C), since
its characteristic peaks are visible at 1700 and 1660 cm1, which
corresponds to the carbonyl stretching vibration of C-17
dihydroxiacetone side chain, and a peak at 1660 cm1 due to
carbonyl stretching vibration of C3 A-ring associated with
the1630 cm1 O–H stretching band of interlamellar water.
3.2.2. BSA release from PHBV MPs
The release proﬁle from BSA-loaded PHBV MPs produced in the
absence of ethanol indicated that 76% of the BSA was released
within the ﬁrst 8 h reaching a release of approximately 78% of the
incorporated BSA that was sustained up to day 21 (Fig. 4A).
Similarly, the BSA loaded-MPs produced in the presence of ethanol
released about 78% of the incorporated BSA within the ﬁrst 8 h.
After 21 days of incubation, approximately 80% of BSA was released
from BSA-loaded PHBV MPs. These results ﬁt the Higuchi model.
The BSA release was conﬁrmed by FTIR analysis (Fig. 4B). The
spectra of BSA-loaded PHBV MPs produced both in the absence and
presence of ethanol, revealed a reduction in the intensity of the
BSA characteristic bands (Fig. 4B) up to 21 days. At this time point,
the presence these were still veriﬁed corresponding to the
remaining protein entrapped in the MPs.
The MPs incorporating BSA, monitored by SEM, showed minor
morphological and topographical alterations after the in vitro
release studies (Fig. 5C). Moreover, MPs structure and integrity was
maintained.
3.2.3. Dex release from PHBV MPs
The release proﬁle of Dex from Dex-loaded PHBV MPs produced
in the absence of ethanol indicated that 55% of Dex was released
within the ﬁrst 8 h and a maximum of approximately 69% of the
incorporated Dex at released up to day 21. In opposition, 89% of the
incorporated Dex in the MPs produced in the presence of ethanol
was released within the ﬁrst 8 h and no Dex was present in the MPs
after 5 days. The release of Dex from the particles obtained in the
absence of ethanol followed the Higuchi model, whereas thex within the PHBV MPs. (B) FTIR spectra of BSA before and after incorporation within
Ps. The characteristic bands of BSA and Dex are highlighted with the gray region.
Fig. 4. BSA release from loaded-PHBV MPs. (A) In vitro release proﬁle of BSA from BSA-loaded PHBV MPs produced under different conditions. (B) FTIR spectra of BSA-loaded
PHBV MPs before and after 21 days of in vitro release. The characteristic bands of BSA are highlighted with the gray region. (C) SEM micrographs of BSA-loaded PHBV MPs
obtained in the (i) absence and (ii) presence of ethanol, after 21 days of in vitro release studies.
Fig. 5. Dex release from loaded-PHBV MPs. (A) In vitro release proﬁle of Dex from Dex-loaded PHBV MPs produced under different conditions. (B) FTIR spectra of Dex-loaded
PHBV MPs before and after 21 days of in vitro release. The characteristic bands of Dex are highlighted with the gray region.
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ethanol ﬁtted the Korsmeyer–Peppas model. Therefore, in this
case, since n is smaller than 0.43, a classical Fickian diffusion is
predicted.
The Dex release from the PHBV MPs was conﬁrmed by FTIR
analysis (Fig. 5B). While the FTIR spectra of Dex-loaded PHBV MPs,
produced in the absence of ethanol, revealed a reduction in theFig. 6. BSA-loaded PHBV MPs embedded in the GG hydrogels visualized by (i) SEM and 
represents a cross-section of the biphasic structure.intensity of the Dex characteristic bands due to the release but a
still present at day 21, those bands were absent in the spectra
corresponding to the Dex-loaded PHBV MPs produced in the
presence of ethanol after the release (Fig. 5B).
As observed for the MPs incorporating BSA, the Dex-loaded
PHBV MPs morphology and shape were not affected by the Dex
release (data not shown).(ii) ﬂuorescence microscopy after FITC labelling. In (i) the upper corner micrograph
Fig. 8. (A) BSA release from loaded-PHBV MPs produced under different conditions
and embedded in 0.75% and 1.25% GG hydrogels. (B) SEM micrographs of the GG
hydrogel containing the BSA loaded-MPs after 21 days of in vitro release studies. The
sequential images represent (i) an overview of the distribution of the particles
within the hydrogel, (ii) a close up on the surface, and (iii) a cross-section.
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3.3.1. Injectable system properties
The embedding of the PHBV MPs produced under different
conditions in the 0.75% and 1.25% (w/v) GG solutions was
conﬁrmed. After gelation, the MPs were homogeneously dispersed
within the hydrogel, maintaining their spherical shape (Fig. 6).
Moreover, PHBV MPs were completely embedded within the GG
matrices, as it is possible to observe in Fig. 6; ii.
The rheological analysis of the GG hydrogel with or without
PHBV MPs, showed that, independently of the concentration of GG,
the sol–gel transition temperature of the systems was around 39 C
(Fig. 7) and gels were formed within 20 s. This temperature was
barely affected by the presence of the PHBV MPs within the
hydrogel, however, as expected the viscosity of the 0.75% GG
(Fig. 7A) was lower than the 1.25% GG hydrogels (Fig. 7B).
Moreover, it was observed that independently of the processing
conditions, the presence of the microparticulate system within the
hydrogel increased its viscosity, nevertheless, was not signiﬁcantly.
3.3.2. BSA release from the injectable GG/PHBV MPs system
The impact of the incorporation of the MPs in the hydrogel over
BSA release proﬁle, showed that the presence of the matrix
surrounding the MPs (Fig. 8A) almost eliminated the release burst
observed for the single MPs suspensions (Fig. 4A). This effect was
more notorious for the 1.25% (w/v) of GG; 35% of the BSA
incorporated in the MPs produced in the absence of ethanol was
released within the ﬁrst 8 h. In contrast, about 40% of the
incorporated BSA was released from the loaded-MPs produced
in the presence of ethanol within the ﬁrst 8 h. Both those values
were the maximum released after 21 days. In contrast, the releaseFig. 7. Rheological behavior of (A) 0.75% and (B) 1.25% GG hydrogels, cproﬁle of BSA from the MPs embedded in the 0.75% GG hydrogel
indicated that 47% of protein was released within the ﬁrst 8 h
reaching a release of approximately 60% and 63% of the
incorporated BSA at day 21, respectively for the BSA loaded-MPs
produced in the absence and in the presence of ethanol.
Interestingly, independently of the concentration of the GG
hydrogel, the release kinetics suggested that the release of BSA
from the tested formulations followed a zero-order release.ontaining or not PHBV MPs produced under different conditions.
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The PHBV MPs were still embedded in the system (Fig. 8C)
although the hydrogel revealed some signs of degradation. The
surface erosion was apparent resulting in the formation of some
cavities. No particles migration was observed after the 21 days of
release studies.
3.3.3. Dex release from the injectable GG/PHBV MPs system
In accordance to what was observed for the BSA-loaded PHBV
MPs embedded in the GG hydrogels, the Dex release proﬁle (Fig. 9)
conﬁrmed that the GG hydrogel surrounding the Dex-loaded MPs
eliminated the initial burst observed for the single MPs suspen-
sions (Fig. 5A). Again, a higher effect observed for the 1.25% GG
systems but in this case, the release proﬁle was not dependent on
the MPs processing conditions as no differences were observed
between the systems produced in the presence and in the absence
of ethanol. Both systems attained a release of around 26% of the
incorporated Dex in the end of the 21 days. Regarding the release
proﬁle of Dex from 0.75% (w/v) GG hydrogels, dependence with the
processing conditions was observed. The MPs produced in the
absence of ethanol released around 20% of the incorporated Dex
within the ﬁrst 8 h reaching approximately 43% of at day 21.
Similarly, the Dex loaded-MPs produced in the presence of ethanol
released about 28% of the incorporated Dex within the ﬁrst 8 h.
However, after 21 days of incubation approximately 52% of Dex
was released from this system. The release kinetics of all these
formulations followed a Korsmeyer–Peppas model, suggesting a
classical Fickian active agent diffusion since n < 0.43.
Moreover, in similarity to what was observed during BSA
release from GG hydrogels, no particle migration from the hydrogel
was noticed.
4. Discussion
Aiming at developing a minimally-invasive DDS we designed a
biphasic injectable DDS that can provide a localized delivery of
MPs avoiding their uncontrolled migration through the human
body, along with a prolonged release of an active agent. For this
purpose, BSA- and Dex-loaded PHBV MPs, processed by a double
emulsiﬁcation–solvent evaporation method with modiﬁcations,
were incorporated into injectable GG hydrogels with different
concentrations.
The solvent type, the concentration of the emulsiﬁer, the
active agent/polymer ratio and the stirring rate are parameters
known to affect the physicochemical properties of the MPs (BazzoFig. 9. Dex release from loaded-PHBV MPs produced under different conditions and
embedded in 0.75% and 1.25% GG hydrogels.et al., 2008). In this regard, a mixture of different solvents, as
organic phase, is herein proposed aiming to tailor the release
proﬁle of hydrophilic and hydrophobic agents by changing the
properties of the particles. While chloroform was selected as the
solvent for the PHBV, ethanol was aimed to improve the mutual
solubility of the organic and the aqueous phases, based on the
type of molecular interactions between the organic solvents
(dipole–dipole) and between ethanol and water (hydrogen bond)
(Poletto et al., 2008). The obtained PHBV MPs had sizes that
ranged from 41.9 to 78.5 mm, depending on the presence of
ethanol, as well as on the type of molecule incorporated. The size
of the MPs in the presence of ethanol in the organic phase was
higher than in its absence. These results are not in accordance to
what was previously reported by Poletto et al. (2008) that showed
a decrease in the size of PHBV nanoparticles when ethanol was
used as a surface agent. The distinct results are probably due to
the differences between the methods used to produce the
particles; while they followed an emulsiﬁcation–diffusion meth-
od, the double emulsiﬁcation–solvent evaporation method herein
proposed involves less high-speed homogenization, which was
previously proved to have a tremendous effect on the particle size
(Mukherjee et al., 2008). Furthermore, the concentration of PHBV
used Poletto et al. (2008) was much smaller than the one we used.
Higher polymer concentrations in the organic phase lead to
increased viscosity of the solution and consequently lower
dispersion thus larger MPs are produced (Kassab et al., 1997;
Yang et al., 2001).
In addition to an effect over particle size, the solvents used
during processing also impact the morphology and topography of
the particles. It was previously reported that when the organic
phase has increased miscibility with water, the interaction
between emulsiﬁer and the aqueous phase increases, thus
particles with rougher surfaces are obtained (Sahoo et al.,
2002). The roughness of the MPs surface has been also associated
to the high crystallinity and fast precipitation of PHBV, after
solvent evaporation from the internal phase of the emulsion
(Bidone et al., 2009). The produced PHBV MPs showed a well-
deﬁned spherical shape independent of the processing conditions.
However, the topography of the surface of the MPs was inﬂuenced
by the presence of ethanol in the process. This ﬁnding is in
accordance with what was stated by others that showed the
ethanol improves the miscibility of both phases and therefore a
better interaction with the emulsiﬁer (Sahoo et al., 2002). The
presence of ethanol also inﬂuenced the inner core porosity of the
particles contrarily to the micro-size porosity found on the PHBV
MPs surfaces observed for all the preparation conditions. The
presence of ethanol on the organic phase led to larger core pores,
which could be attributed to the hydrophobicity of PHBV. During
the ﬁrst emulsiﬁcation, water droplets (ﬁrst aqueous phase)
interact with the ethanol present in the organic phase, but the
same is not observed when the organic phase is composed only by
chloroform. In this sense, the presence of ethanol in the organic
phase leads to the formation of larger droplets inside the dispersed
phase and consequently to larger pores after removal of the water
droplets by freeze-drying, in accordance to what was previously
reported in the literature (Zhu et al., 2007).
The incorporation of BSA and Dex within the PHBV MPs also
affected their properties. An increase in the mean size was observed
for the loaded-PHBV MPs, proportional to the MW of the
incorporated active agent. The BSA-loaded MPs, incorporating the
protein with a MW of 66 kDa, exhibited larger mean size than Dex-
loaded MPs that have entrapped a molecule with a MWof 392.46 Da.
The incorporation of active agents is highly dependent on the
chemical structure and MW of the molecules, as well as on the
hydrophobicity of the polymers (Park et al., 2005). In this study,
BSA IE revealed to be independent of the organic phase
406 D.P. Pacheco et al. / International Journal of Pharmaceutics 478 (2015) 398–408composition, which was also observed for the IE of Dex. However,
the active agent IE was affected by its MW, since Dex had a
signiﬁcantly higher IE than BSA. These results are in accordance
with Lionzo et al. (Lionzo et al., 2007) that proposed a general
single emulsiﬁcation–solvent evaporation method for the incor-
poration of Dex within PHBV MPs.
The in vitro release proﬁle of a molecule entrapped in
polymeric MPs/matrix is controlled by a variety of factors, such
as the solubility of the molecules in the surrounding media, its
MW and mobility within the swollen polymeric network, as well
as the interactions of the polymer with the active agent (Embleton
and Tighe, 1993; Sah et al., 1994; Giunchedi et al., 1994; Igartua
et al., 1997; Yang et al., 2001). Moreover, other features such as the
morphology, size and size distribution of the particles also
inﬂuence the release kinetics. These represent the ones that can
be controlled by varying the processing conditions. Although
PHAs have been described as high crystalline polymers, the reason
for its slow degradation, excessive release rates from PHAs MPs
have been previously and consistently reported, and assumed to
be mainly dependent on active agent dissolution rather than
matrix degradation (Bidone et al., 2009). This is in agreement
with our results that conﬁrmed structurally intact and spherical
shape MPs after the release studies. We also found that the Dex
amount released from the Dex-loaded PHBV MPs produced in the
absence of ethanol was minor than for the MPs produced in the
presence of ethanol. This ﬁnding was expected since the addition
of ethanol to the organic phase led to the formation of particles
with larger inner pores that facilitated the water penetration.
Regarding the BSA, the release studies revealed no signiﬁcant
differences when ethanol was added to the organic phase, and a
release of around 78% of the incorporated protein was observed
after 21 days of immersion. Thus, it was also observed that the
MW of the incorporated active agents did not only affect the IE but
also the amount of active agent released. Due to its lower MW,
Dex had higher ability to diffuse across the polymeric matrix,
corroborating the fact that the amount of small molecules
released is commonly higher than proteins.
In this sense, MPs composed by PHBV with tuned surface
topography, size distribution and core porosity were obtained
using simple variations of the composition of the organic phase
during processing. The in vitro release proﬁle of Dex but not of BSA,
was also affected allowing the control over the amount of Dex
release along the time.
Nonetheless, a biphasic systems with a uniform distribution of
PHBV MPs across the GG matrix, and the ability to be injected into
the organism and with gelation occurring approximately at the
body temperature, as previously reported (Oliveira et al., 2010),
was developed.
The combination of active agent-loaded MPs with in situ gelling
system was tried by a few groups with various particle-embedded
hydrogels (Lagarce et al., 2005; Defail et al., 2006). In these studies,
it was noticeable that during the in vitro release studies the amount
of active agent release was decreasing, having a higher impact
during the ﬁrst hours, whose burst effect was almost eliminated.
The incorporation of the MPs into the GG hydrogels strongly
inﬂuenced both the proﬁle and the amount of BSA and Dex
released. As expected, hydrogels of higher GG concentration lead to
a slower and more sustained release, independently of the
processing conditions of the microparticulate system due to the
higher density of the hydrogel which reduces the active agent
diffusion. Moreover, the initial burst effect and the previously
observed differences with the processing conditions, more
notoriously for the 1.25% GG hydrogels, were attenuated. Active
agents entrapped inside MPs have to diffuse through two barriers
(particulate system and hydrogel) to be released into the
surrounding media, which can reduce the burst effect and prolongthe delivery (Chen et al., 2004; Sivakumaran et al., 2011). Thus,
along with the time, the amount of released active agent will be
mainly dependent on the degradation of the hydrogel. After 21
days of incubation, the GG hydrogels presented some signs of
degradation after immersed in PBS for 3 weeks, which can be
explained by hydrolytic reactions (Coutinho et al., 2010). However,
a strong integration of the microparticulate system within the GG
matrix was observed, even after the release studies, which shows
the superior ability of these systems to maintain the particles
within the defect site.
In summary, this work conﬁrmed the capacity of PHBV
microparticulate systems to deliver both hydrophilic and hydro-
phobic active agents, and determined how the organic phase
composition can be deﬁned to tailor their incorporation and
respective release proﬁle. Moreover, the embedding of these
systems in injectable hydrogels conﬁrmed that the proposed
system provides a localized delivery avoiding uncontrolled
migration, along with a sustained release of the active agents.
5. Conclusion
The main goal of this work was to propose a biphasic injectable
DDS based on the combination of microparticulate systems
and an injectable hydrogel for the localized delivery and long-
term retention of MPs carrying hydrophilic and hydrophobic
model active agents relevant for RM purposes, thus guaranteeing
a prolonged release. In this sense, injectable GG hydrogels
entrapping Dex- or BSA-loaded PHBV MPs were developed.
Such platform was characterized by a prolonged release, which
proﬁle can be tailored according to the MPs and hydrogel features.
The proposed system also offers the advantage of a high
spatial control over the defect ﬁlling by a fast gelation at the
injection site. Thus, the combination of an injectable GG hydrogel
with Dex- or BSA-loaded PHBV MPs represents a promising
strategy to deliver multiple active agents with distinct kinetics,
which is likely required to drive tissue development to
regeneration.
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